Perhaps - but amgen already have the market.
Imagine how Amgen's shareholders would feel in 3 years when another one of their revenue streams flounders due to the inaction of management after being publicly called out by a relatively unknown asx bio. It's worth noting that carfilzomib's revenue has increased recently due to combination treatment with Darzalex (J&J).
Do we know anyone from J&J?
Perhaps - but amgen already have the market. Imagine how...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.020(1.27%) |
Mkt cap ! $266.3M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.61 | $1.58 | $10.25K | 6.468K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2807 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 100 | 1 |
View Market Depth
| Last trade - 10.34am 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.59 |
Change
0.020 ( 1.31 %) |
||||
| Open | High | Low | Volume | ||
| $1.60 | $1.60 | $1.59 | 22 | ||
| Last updated 10.46am 06/06/2024 ? | |||||
| RAC (ASX) Chart |